- Home
- CXH vs BEAT Comparison
CXH vs BEAT Comparison
Compare CXH & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXH
- BEAT
- Stock Information
- Founded
- CXH 1989
- BEAT 2015
- Country
- CXH United States
- BEAT United States
- Employees
- CXH N/A
- BEAT N/A
- Industry
- CXH Investment Managers
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- CXH Finance
- BEAT Technology
- Exchange
- CXH Nasdaq
- BEAT Nasdaq
- Market Cap
- CXH 65.6M
- BEAT 63.5M
- IPO Year
- CXH N/A
- BEAT 2021
- Fundamental
- Price
- CXH $7.99
- BEAT $1.65
- Analyst Decision
- CXH
- BEAT Buy
- Analyst Count
- CXH 0
- BEAT 1
- Target Price
- CXH N/A
- BEAT $8.00
- AVG Volume (30 Days)
- CXH 25.9K
- BEAT 83.0K
- Earning Date
- CXH 01-01-0001
- BEAT 11-13-2025
- Dividend Yield
- CXH 3.56%
- BEAT N/A
- EPS Growth
- CXH N/A
- BEAT N/A
- EPS
- CXH 0.23
- BEAT N/A
- Revenue
- CXH N/A
- BEAT N/A
- Revenue This Year
- CXH N/A
- BEAT N/A
- Revenue Next Year
- CXH N/A
- BEAT $19.35
- P/E Ratio
- CXH $33.35
- BEAT N/A
- Revenue Growth
- CXH N/A
- BEAT N/A
- 52 Week Low
- CXH $6.41
- BEAT $0.91
- 52 Week High
- CXH $7.74
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- CXH 62.21
- BEAT 49.74
- Support Level
- CXH $7.97
- BEAT $1.55
- Resistance Level
- CXH $8.04
- BEAT $1.85
- Average True Range (ATR)
- CXH 0.04
- BEAT 0.12
- MACD
- CXH -0.01
- BEAT -0.01
- Stochastic Oscillator
- CXH 53.39
- BEAT 47.37
About CXH MFS Investment Grade Municipal Trust
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.